Drug discontinuation: Mesalamine Capsule, Extended Release (PENTASA, MESALAMINE)
FDA lists 3 presentations as To Be Discontinued. Companies: Takeda Pharmaceuticals USA Inc., Mylan Pharmaceuticals Inc., a Viatris Company.
- Published by source
- 2026-08-25
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Takeda Pharmaceuticals USA Inc.
- Products
- Mesalamine Capsule, Extended Release PENTASA MESALAMINE
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- Product is anticipated to be available until December 31, 2027
- Discontinuation of the manufacture of the drug
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-08-25
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #982 | new | 2026-10-22 | 6ee00cd3472d…1668c0 | b453f3ac5a87…39026c |
Chain head: #1076 8ad5adc30b9b…88ce20